Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 18, 2011

View Archived Issues

Results made available from MENZA trial of enzastaurin

First-in-patient study assesses EMD-525797 in metastatic CRPC

Antifibrinolytic MDCO-2010 safe in first-in-patient trial

Roche to expand HCV portfolio with acquisition of Anadys

Anadys reports interim data from setrobuvir study

Controlled-release phentermine/topiramate formulation shows long-term benefit in obesity

Rib-X Pharmaceuticals describes RX-04 program for developing novel antibiotics

Scientists at Roche present novel farnesoid X receptor agonists

New monoamine reuptake inhibitors synthesized by NeuroSearch

Novo Nordisk prepares new glucagon receptor agonists

Krisani Biosciences patents new pain therapeutics

Novel autotaxin inhibitors designed by Merck KGaA

ABI-007 advances through trial in gastric cancer

Ube and Santen form prostanoid EP2 receptor agonist collaboration

ULURU to out-license European rights to Altrazeal

FDA grants accelerated approval to ApoPharma's Ferriprox

VIVUS resubmits NDA for Qnexa

Dendreon begins enrollment in phase II trial of DN24-02

NeoStem acquires Amorcyte and plans phase II stem cell therapy trial

OTSA-101 clear to enter clinic in France

Infinity Pharmaceuticals provides update on IPI-926 trials

Archimedes Pharma launches Lazanda

TONIX Pharmaceuticals completes reverse merger transaction

ChemoCentryx begins phase II CCX-168 trial

AB Science recruits first patient in phase III masitinib trial

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
AIDS 2026: New targets for metabolic dysfunction despite ART
BioWorld
Although antiretroviral therapy (ART) can suppress HIV to undetectable levels, a growing body of evidence suggests that the virus leaves a lasting biological...
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Jingxin discloses new muscarinic and sigma receptor agonists
BioWorld Science
Shanghai Jingxin Biopharmaceutical Co. Ltd. and Zhejiang Jingxin Pharmaceutical Co. Ltd. have synthesized new muscarinic acetylcholine receptor and sigma receptor...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...